Hair loss · Medical treatment
Finasteride, minoxidil & PRP:
what the evidence says.
A transplant moves hair that resists pattern loss, but the hair around it keeps its genetic programme. Medicines are what slow that loss. Here's what the trials found, the side effects that are on the label, and how weak or strong the evidence is for the add-ons clinics sell.
Quick answer
Do I need finasteride or minoxidil after a hair transplant?
Often yes. Transplanted follicles resist pattern loss, but your native hair does not, so loss can continue around the grafts. In the pivotal trials, men on finasteride 1 mg had 107 more hairs than placebo at one year and 138 more at two years in a 1-inch circle, while men on placebo kept losing hair. Topical 5% minoxidil gave 45% more regrowth than 2% at 48 weeks. Your doctor will weigh side effects; sexual side effects on finasteride were 3.8% vs 2.1% with placebo in year one.
+138 hairs
Finasteride vs placebo, 2 years
In a 1-inch (5.1 cm²) vertex circle; 1,553 men aged 18–41
Kaufman et al., JAAD 1998
3.8% vs 2.1%
Sexual side effects, year 1
Finasteride vs placebo; each ≤0.3% by year 5
PROPECIA US label
45%
More regrowth, 5% vs 2% minoxidil
Men, 48 weeks, 393 participants
Olsen et al., JAAD 2002
Not superior
Oral 5 mg vs topical 5% minoxidil
24-week RCT; 49% had extra body/facial hair on oral
Penha et al., JAMA Dermatol 2024
Low
Certainty of PRP evidence
+27.6 hairs/cm² vs placebo, 14 RCTs, very high heterogeneity
Kieling et al., An Bras Dermatol 2024
510(k)
FDA status of laser combs
Cleared (not approved) since 2007
FDA K060305
The options
From strongest evidence to weakest.
Finasteride 1 mg (oral)
Blocks conversion of testosterone to DHT. Durable benefit over five years in trials. Not for women who are or may become pregnant.
Prescription
Minoxidil (topical)
5% solution or foam. Prolongs the growth phase. Can cause scalp irritation; hair gains are lost if you stop.
Over the counter in many countries
Dutasteride / oral minoxidil
Stronger or more convenient alternatives that some dermatologists use off-label. Promising data, but fewer long-term trials.
Specialist decision
PRP, laser devices
May add some density, but evidence quality is low and protocols vary. Not a replacement for medication.
Optional
Side by side
Hair-loss treatments compared
Figures come from the trials and reviews listed below. Results are averages for groups of people; they aren't predictions for you.
| Treatment | Key evidence | Side effects to know |
|---|---|---|
| Finasteride 1 mg daily | +107 hairs at 1 yr, +138 at 2 yrs vs placebo (1,553 men); durable over 5 years | Label, year 1: decreased libido 1.8% vs 1.3%, erectile dysfunction 1.3% vs 0.7%, ejaculation disorder 1.2% vs 0.7% |
| Dutasteride 0.5 mg daily | Beat finasteride on hair count and width at 24 weeks (917 men) | Similar to finasteride in that trial; off-label for hair in many countries |
| Topical minoxidil 5% | 45% more regrowth than 2% at 48 weeks | More scalp itching and irritation than 2% |
| Oral minoxidil 5 mg | Not superior to topical 5% at 24 weeks (68 men completed) | Extra body/facial hair 49%, headache 14% |
| Low-dose oral minoxidil | Safety series of 1,404 patients (no control group) | Extra hair 15.1%, light-headedness 1.7%, fluid retention 1.3%; 1.7% stopped |
| PRP injections | +27.6 hairs/cm² vs placebo; GRADE low certainty, publication bias | Injection pain; protocols not standardised |
| Low-level laser (LLLT) | More terminal hairs than sham at 26 weeks (269 people) | Few; FDA 510(k)-cleared devices |
Sources: Kaufman 1998; Finasteride Study Group 2002; PROPECIA label; Gubelin Harcha 2014; Olsen 2002; Penha 2024; Vañó-Galván 2021; Kieling 2024; Jimenez 2014.
Finasteride safety
What the label says, and what's still debated
In the year-one trial data on the US label, sexual side effects occurred in 3.8% of men on finasteride versus 2.1% on placebo. Rates fell to 0.3% or less by year five. The label's post-marketing section also lists sexual dysfunction that continued after stopping the drug, male infertility or poor semen quality, male breast cancer, and depression, suicidal ideation and behaviour.
A 2015 JAMA Dermatology meta-analysis found that none of 34 finasteride hair-loss trials reported safety adequately, and most followed patients for a year or less. Rare or persistent effects may therefore be under-counted. Finasteride lowers PSA, so tell any doctor checking your prostate that you take it. In 2025 the FDA warned about compounded topical finasteride products and noted that no topical finasteride is FDA-approved.
Hair-loss medicine
Dermatology departments
that treat hair loss.
Huashan Hospital, Fudan University — Dermatology 复旦大学附属华山医院皮肤科
Hair-loss medicine; international department (Huashan Worldwide Medical Center) since 1989
Peking Union Medical College Hospital — Dermatology 北京协和医院皮肤科
Hair-disorder clinic opened January 2026 — diagnosis and medical treatment, not surgery
FAQ
Medication questions — answered.
- How long does finasteride take to work?
- Trials measured results at one and two years, with benefit maintained over five years. Many people notice less shedding first. Your doctor will usually review progress after several months.
- What happens if I stop finasteride or minoxidil?
- The benefit is gradually lost. Both slow or partly reverse ongoing loss, but neither cures it. Transplanted hair is not dependent on them; your native hair is.
- Is oral minoxidil better than the topical form?
- In a 2024 randomised trial of 5 mg oral versus 5% topical twice daily, oral minoxidil was not superior overall at 24 weeks, though it did better on photo assessment of the crown. Nearly half had extra body or facial hair. Lower oral doses (0.25–5 mg) are used off-label by some dermatologists; a 1,404-patient safety series found few serious problems, but it had no control group.
- Does PRP work for hair loss?
- It may add some density. A 2024 meta-analysis of 14 RCTs found +27.6 hairs/cm² compared with placebo, but rated the evidence low quality, with very high heterogeneity and signs of publication bias. Adding PRP to minoxidil showed a benefit in another 2024 review, with low to very low certainty.
- Do laser caps work?
- A sham-controlled trial of 269 men and women found more terminal hairs with the laser device at 26 weeks. These devices are FDA 510(k)-cleared, which is not the same as drug-style approval. They're an option, not a substitute for medication.
- Can I take finasteride as a woman?
- The US label says finasteride is not indicated for women, and pregnant women should not handle crushed or broken tablets because of the risk to a male fetus. A Cochrane review found finasteride 1 mg no better than placebo for female pattern hair loss. See our female hair loss page.
Related guides
Hair transplant in China (hub)
Who it suits, how it's regulated, hospitals and the whole timeline.
Read the guideFUE vs FUT
Two ways to harvest grafts: scars, yield and who suits which.
Read the guideAm I a candidate?
Norwood stages, donor area, age, and when surgery is the wrong answer.
Read the guideRecovery timeline
Day 1 to month 18: washing, shedding, regrowth and the final result.
Read the guideFemale pattern hair loss
Diagnosis, minoxidil, spironolactone, and when women suit a transplant.
Read the guideHair transplant tours
Beijing and Shanghai routes at public hospitals, with recovery-friendly sightseeing.
Read the guideMedical aesthetics in China
Toxin, fillers, lasers and eyelid surgery — and how to check a clinic.
Read the guideSources
References
- Kaufman KD, Olsen EA, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578–589.
- Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38–49.
- PROPECIA (finasteride) tablets — US prescribing information (Organon, NDA 020788), DailyMed.
- Belknap SM, et al. Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis. JAMA Dermatol. 2015;151(6):600–606.
- US FDA. FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products (2025).
- Gubelin Harcha W, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.e3.
- Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385.
- Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600–605.
- Vañó-Galván S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644–1651.
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141.e5.
- Kieling L, et al. Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? A systematic review and meta-analysis of randomized clinical trials. An Bras Dermatol. 2024;99(6):847–862.
- Yao J, et al. The additive value of platelet-rich plasma to topical minoxidil in the treatment of androgenetic alopecia: a systematic review and meta-analysis. PLoS One. 2024;19(8):e0308986.
- US FDA 510(k) premarket notification K060305 — HairMax LaserComb, cleared 18 January 2007 (substantially equivalent).
- Jimenez JJ, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014;15(2):115–127.
- van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;(5):CD007628.
- Vañó-Galván S, et al. An international expert consensus statement focusing on pre and post hair transplantation care. J Dermatolog Treat. 2023;34(1):2232065.
Want a plan that protects
the hair you still have?
A dermatology consultation in China can confirm the cause of your hair loss and give you a written treatment plan your doctor at home can continue.
This page is for general education only and is not medical advice. Whether a hair transplant or a medicine suits you depends on the cause and pattern of your hair loss, your donor area, your age and your health, and only a doctor who examines you can decide. Trial results describe groups of people, not what will happen to you. We are an independent patient-coordination service; we are not affiliated with any clinic chain or drug manufacturer and do not publish graft prices.
Published 7 November 2026 · Figures checked against the cited sources by the PandaTouring Care editorial team · Editorial policy